Infusense
Nashville, US · Tennessee corporation · 1 known investors
InfuSense develops an electrochemical sensing technology platform that detects analytes at sub-therapeutic levels, delivering sample analysis results within minutes. The portable device is designed to bring laboratory-scale testing capabilities into a handheld form factor.
Also known as InfuSense
Founders & leadership
Board
Investors · 1
Reported raises · per SEC filings
Form D private placements$2M disclosed across 2 rounds · 2015–2025
▶$1.4MraisedJun 2025 · 21 investors · Other TechnologyRule 506(b)
- ANDY SASLAWSKYDirector
- BRUCE LANDAUDirector
- EDWARD CHAUMDirector
- Eric KriegsteinExecutive Officer
- Offering amount
- $2M
- Amount sold
- $1.4M
- Minimum investment
- $5K
- First sale
- May 2025
- Incorporated
- Corporation, Tennessee
- Federal exemptions
- 06b
▶$600KraisedDec 2015 · 6 investors · BiotechnologyRule 506(b)
- Edward ChaumExecutive Officer, Director
- Offering amount
- $600K
- Amount sold
- $600K
- First sale
- Dec 2015
- Incorporated
- Corporation, Tennessee
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Company profile
researched Aug 2026Infusense is a Nashville-based biosensor company developing an electrochemical technology platform for drug quantification. The platform is presented as achieving analyte detection limits at sub-therapeutic levels, with sample analysis completed in a few minutes.
The company's stated approach uses electrochemistry (voltammetric measurement) to measure target analytes, with the aim of delivering full-scale laboratory measurement capability in a handheld form factor. Publications listed by the company cover electrochemical sensors for tricyclic antidepressants (amitriptyline and nortriptyline in blood) with low nanomolar detection limits, polymeric and plasticized PVC membrane-modified voltammetric sensors for lipophilic and highly hydrophobic compounds, and voltammetric measurement of propofol (2,6-diisopropylphenol) in serum-like electrolyte solutions oriented toward feedback-controlled anesthesia. A publicly announced program targets a rapid fentanyl toxicity test.
Traction
Infusense reported a $1 million NSF SBIR grant to advance a rapid fentanyl toxicity test and an SBIR/STTR matching funds award from Launch Tennessee. The company was scheduled to present at LSTCON 2024, the Life Science Tennessee conference, and has been featured in Teknovation.Biz coverage. Its scientific work appears in peer-reviewed literature indexed by the National Library of Medicine, ScienceDirect and ACS Publications.
▸Full profile — market position, technology, go-to-market, geography, history
Market position
Infusense positions its platform as bringing laboratory-scale drug quantification into a portable, point-of-need format, with applications in drug toxicity testing and anesthesia monitoring.
Technology
The core technology is an electrochemical (voltammetric) sensing modality, including polymeric membrane-modified and plasticized PVC membrane-modified electrodes, used to quantify lipophilic and highly hydrophobic compounds. Reported characteristics include nanomolar and sub-therapeutic detection limits and sample analysis times of a few minutes, with the electrochemical approach enabling a handheld, palm-sized device rather than laboratory instrumentation. Application areas indicated by company-listed publications and programs include tricyclic antidepressants (amitriptyline, nortriptyline) in blood, propofol measurement for feedback-controlled anesthesia, and fentanyl toxicity testing.
Go-to-market
Clinical and point-of-care settings requiring rapid drug quantification, including toxicity testing (fentanyl) and anesthesia monitoring (propofol).
Geography
Headquartered in Nashville, Tennessee, United States, with ties to Tennessee-based organizations including Life Science Tennessee and Launch Tennessee.
History
Edward Chaum, M.D., Ph.D., is identified as founder and chairman of the board. The company's website carries a 2023 copyright notice, and reported milestones include a 2023 Innovation Award to advisor Dr. Erno Lindner, an NSF SBIR grant of $1 million for a rapid fentanyl toxicity test, an SBIR/STTR matching funds award from Launch Tennessee, and a scheduled presentation at LSTCON 2024.
Compiled by commissioned research from 1 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Competitors · 3
by search overlap
Companies competing with Infusense for the same Google search keywords, organic and paid, via search-intersection analysis.
Non-dilutive funding · 3 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Science Foundation | Phase II | 2023 | $999.9K |
| National Science Foundation | Phase I | 2021 | $253.6K |
| Department of DefenseDefense Health Program | Phase I | 2013 | $150K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Timeline · 4
launches, deals, and filingsCompany reported an NSF SBIR grant of $1 million to advance a rapid fentanyl toxicity test.
$1M source ↗
Company scheduled to present at the Life Science Tennessee conference LSTCON 2024.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
Legal entities · 1
corporate structureIn the news
▸Research sources · 1
primary sources listed
- Infusenseinfusense.com · web
1 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Infusense do?
- Infusense develops an electrochemical biosensor platform for rapid, handheld quantification of drugs in samples.
- Who are Infusense's investors?
- Infusense's investors include Evolution VC Partners.
- How much funding has Infusense raised?
- Infusense has disclosed $2M raised across 2 rounds.
- Where is Infusense headquartered?
- Infusense is headquartered in Nashville, US.